학술논문
FKB327, an adalimumab biosimilar, versus the reference product: results of a randomized, Phase III, double-blind study, and its open-label extension.
Document Type
Article
Author
Source
Arthritis Research & Therapy; 12/12/2019, Vol. 21 Issue 1, p1-12, 12p
Subject
Language
ISSN
14786354